SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.

Otros idiomas Shin Nippon Biomedical Laboratories, Ltd.

Acciones

2395

JP3379950003

Diferido Japan Exchange Otros sitios de cotización 08:00:00 17/05/2024			Varia. Cinco días.	Varia. 1 de enero.
1.375 ^JPY	-1,15 %		-1,93 %	-19,02 %

02/02	Shin Nippon Biomedical Laboratories, Ltd. Ofrece una previsión de beneficios consolidados para el año que finaliza el 31 de marzo de 2024	CI
2023	Shin Nippon Biomedical Laboratories, Ltd. Proporciona la orientación de ganancias consolidadas para los seis meses que terminan el 30 de septiembre de 2023 y el año completo que termina el 31 de marzo de 2024	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2024	02/02
Shin Nippon's STS101 Faces Regulatory Hurdle, FDA Requests Refinement for Approval	18/01
Shin Nippon Biomedical Laboratories : 英語版株主通信（2023/04/01~2023/09/30）を発行しました	27/12
Shin Nippon Biomedical Laboratories, Ltd. Announces Interim Dividend for the Year Ending March 31, 2024, Payable on November 30, 2023; Provides Dividend Guidance for the Year Ending March 31, 2024	07/11
Shin Nippon Biomedical Laboratories, Ltd. Provides Dividend Guidance for Second Quarter and Full Year Ending March 31, 2024	02/08/23
Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2023 and Full Year Ending March 31, 2024	02/08/23
Satsuma Pharmaceuticals and SNBL Announce Three Abstracts on STS101 for the Acute Treatment of Migraine to be presented at the American Headache Society's 65th Annual Scientific Meeting	16/06/23
Satsuma Pharmaceuticals and SNBL Announce Three Abstracts on STS101 for the Acute Treatment of Migraine to be Presented at the American Headache Society’s 65th Annual Scientific Meeting	15/06/23
Satsuma Pharmaceuticals and Shin Nippon Biomedical Laboratories, Ltd. Announce Three Abstracts on STS101 for the Acute Treatment of Migraine to Be Presented at the American Headache Society's 65th Annual Scientific Meeting	15/06/23
Shin Nippon Biomedical Laboratories, Ltd. completed the acquisition of the remaining 91.6% stake in Satsuma Pharmaceuticals, Inc. from a group of sellers.	08/06/23
Shin Nippon Biomedical Laboratories, Ltd. Reports Earnings Results for the Full Year Ended March 31, 2023	08/05/23
Shin Nippon Biomedical Laboratories, Ltd. Provides Dividend Guidance for Second Quarter and Full Year Ending March 31, 2024	08/05/23
Shin Nippon Biomedical Laboratories, Ltd. Announces Year End Dividend for the Year Ended March 31, 2023, Payable on June 28, 2023	08/05/23
Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2023 and Full Year Ending March 31, 2024	08/05/23
Shin Nippon Biomedical to Make $30 Million Offer for US-based Satsuma Pharmaceuticals	18/04/23
Sector Update: Health Care Stocks Higher Premarket Monday	17/04/23
Bank Earnings in Focus as US Equity Futures Tread Water	17/04/23
Top Premarket Gainers	17/04/23
Satsuma Pharmaceuticals to be Acquired by Shin Nippon Biomedical	17/04/23
Shin Nippon Biomedical Laboratories, Ltd. entered into an agreement to acquire the remaining 91.6% stake in Satsuma Pharmaceuticals, Inc. from a group of sellers for $27.6 million.	17/04/23

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Shin Nippon Biomedical Laboratories, Ltd.

Acciones

2395

JP3379950003

Otros idiomas

Filtros